Lower extremity ischemic disease is mainly caused by arteriosclerotic obliterans, diabetes and thromboangiitis obliterans, which is a serious health hazard and high disability rate, and its incidence increases significantly with the increase of age. chitosan is made by deacetylation of chitin, which is widely existed in nature, and it has good blood compatibility, high safety, strong microbial degradability, anti-inflammatory, immunomodulatory, anti-tumor, and anti-oxidation properties. An article published in Carbohydrate Polymers by Hongtao Liu and Haiming Hu of Hubei University of Chinese Medicine explores the beneficial effect of chitosan oligosaccharides in a mouse model of hind limb ischemia, and points out the potential role of chitosan oligosaccharides in the treatment of peripheral ischemic disease.
A mouse model of posterior limb ischemia was established by femoral artery ligation to explore the potential mechanism of COS in the treatment of posterior limb ischemia.
COS treatment promotes blood perfusion and new blood vessel formation in mice with hind limb ischemia, and inhibits inflammatory response and oxidative stress;
COS can partially restore the intestinal flora imbalance caused by hind limb ischemia in mice;
COS can further regulate the level of plasma metabolites in mice with hind limb ischemia, mainly up-regulating the angiogenesis pathway;
COS can significantly prevent posterior limb ischemia in femoral artery ligation mice;
The changes in the abundance of specific species of intestinal flora were correlated with changes in physiology and metabolite levels of mice with hind limb ischemia.
10.1016/j.carbpol.2020.116271
BZ Oligo mainly offer marine oligosaccharide standards and ingredients, containing alginate oligosaccharide, chitosan oligosaccharide, agar oligosaccharide and carrageenan oligosaccharide, which give business opportunities using these untapped oligosaccharides for biological applications targeting lab research, pharmacy, dietary supplement, sustainable agriculture and animal health.
Factory